Pfizer says ELREXFIO meets primary endpoint in Phase 3 MagnetisMM-32 trial

Pfizer announced topline results from the Phase 3 MagnetisMM-32 trial of ELREXFIO showed clinically meaningful and statistically significant benefit for patients whose disease progressed after anti-CD38 therapy and lenalidomide, with median progression-free survival not yet reached.

Detected & updated continuously · Source: Nebula